<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966261</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A01632-53</org_study_id>
    <nct_id>NCT03966261</nct_id>
  </id_info>
  <brief_title>The Role of Incretins in Bone Remodeling in Humans</brief_title>
  <acronym>INCREMOS</acronym>
  <official_title>INcrétines et REModelage OSseux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of incretins (GIP and GLP-1) on cells and bone tissue has been shown in cellular and
      animal studies. In humans, the role of these hormones is mainly studied in the
      pathophysiology of diabetes, their effect on bone is unknown. The serum incretin
      concentration is low and increases rapidly after a meal. This increase is brief, incretins
      being rapidly degraded by dipeptidylpeptidase 4 (DPP-4). The dosage of these hormones is
      complex and the basal &quot;normal&quot; serum concentrations and after feeding in healthy subjects are
      unknown. Before any study on the effect of incretins on bone remodeling in humans, it is
      necessary to establish physiological concentrations of incretins in healthy subjects.

      The aim of this study is to estimate physiological concentrations of incretins in healthy
      subject.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incretins concentrations before and after a meal in healthy subjects</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Incretins</condition>
  <condition>Osteoporosis</condition>
  <condition>Bone Remodeling</condition>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>we perform blood sample in healthy subject before and after a meal to measure incretins concentration</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy women and men aged from 30 to 70 years without bone patholog nor pathological
        condition influencing bone remodeling nor treatment influencing bone remodeling
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy women and men

        Exclusion Criteria:

          -  known osteoporosis

          -  osteoporotic fracture

          -  tobacco

          -  alcohol : &gt; 2 glasses/day

          -  type 1 and type 2 diabetes

          -  BMI &lt; 19kg/m² or &gt; 30kg/m²

          -  heart failure, kidney failure

          -  cancer

          -  bariatric surgery

          -  graft

          -  cirrhosis

          -  use in the past year : bisphosphonate, denosumab, raloxifene, teriparatide, oral or IV
             glucocorticoid during 3 months or more
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benoit GOBRON, Dr</last_name>
    <phone>+33241353576</phone>
    <email>Benoit.Gobron@chu-angers.fr</email>
  </overall_contact>
  <reference>
    <citation>Mabilleau G. Interplay between bone and incretin hormones: A review. Morphologie. 2017 Mar;101(332):9-18. doi: 10.1016/j.morpho.2016.06.004. Epub 2016 Aug 8. Review.</citation>
    <PMID>27423214</PMID>
  </reference>
  <reference>
    <citation>Mabilleau G, Gobron B, Mieczkowska A, Perrot R, Chappard D. Efficacy of targeting bone-specific GIP receptor in ovariectomy-induced bone loss. J Endocrinol. 2018 Aug 18. pii: JOE-18-0214. doi: 10.1530/JOE-18-0214. [Epub ahead of print]</citation>
    <PMID>30121578</PMID>
  </reference>
  <reference>
    <citation>Mabilleau G, Gobron B, Bouvard B, Chappard D. Incretin-based therapy for the treatment of bone fragility in diabetes mellitus. Peptides. 2018 Feb;100:108-113. doi: 10.1016/j.peptides.2017.12.008. Review.</citation>
    <PMID>29412811</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

